Ociperlimab
Ociperlimab Basic information
- Product Name:
- Ociperlimab
- Synonyms:
-
- Ociperlimab
- Research Grade Ociperlimab (DHH72405)
- Research Grade Ociperlimab
- Ociperlimab (anti-TIGIT)
- CAS:
- 2342597-93-5
- MW:
- 0
- Mol File:
- Mol File
Ociperlimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Ociperlimab Usage And Synthesis
Uses
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer[1][2].
in vivo
Ociperlimab (BGB-A1217; 3 and 10 mg/kg; i.p.; CT26 WT tumor-bearing humanized TIGIT knock-in mice and MC38 tumor-bearing humanized TIGIT knock-in mice) elicits anti-tumor efficacy in an Fc-dependent manner[1].
| Animal Model: | CT26 WT tumor-bearing humanized TIGIT knock-in mice and MC38 tumor-bearing humanized TIGIT knock-in mice[1] |
| Dosage: | 3 and 10 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Inhibited tumor growth compared to the single agent treatment groups. |
References
[1] Chen X, et, al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. Front Immunol. 2022 Feb 22;13:828319. DOI:10.3389/fimmu.2022.828319
[2] Zhu J, et, al. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation. Mol Biol Rep. 2022 Dec 26. DOI:10.1007/s11033-022-08220-4
OciperlimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com